Customized vaccines and therapies based on platform technology.
mRNA Vaccine Platform
Research and development of an artificial intelligence-based structural platform for the development of next-generation customized mRNA-based vaccines.
Phase 1 (2022)
Design of augmented mRNA structural elements based on deep learning
Phase 2 (2023)
Optimization of integrated augmented mRNA structures
Phase 3 (2024)
Advanced development of augmented mRNA vaccine platform and confirmation of immunogenicity
(Source: Nature Biotechnology | VOL 37 | JULY 2019)
Phase 4 (2025)
Assessment of defensive capability and toxicity of augmented mRNA vaccine platform
Vx Product (New Drug) Pipeline
(As of August 2023)
| Disease | Research | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
| Treatments for respiratory disease | |||||
| Diabetes/obesity treatment | |||||
| Pediatric Weaning Adaptive treatment | |||||
| Anti-cancer antibody treatment | |||||
| Anti-cancer RNA treatment | |||||
| Gene Delivery System Research |
Anti-Cancer Monoclonal Antibodies
(As of August 2023)
| Pipelines | Indications | Detailed planning | 2023 3Q | 2023 4Q | 2024 1Q | 2024 2Q | 2024 3Q | 2024 4Q | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Antibody new drugs | Anticancer | Building libraries | |||||||
| Screening | |||||||||
| Antibody optimization | |||||||||
| Validation | |||||||||
| Antibody production and preclinical initiation |
Anti-cancer monoclonal antibody drug (code 00)
Our company is developing a monoclonal antibody drug that targets proteins that are specifically overexpressed in cancer cells, inducing cancer cell-specific cell death. Currently, (code 00) is in the early stage of library construction development, and we plan to initiate preclinical trials by the end of 2024.
Anti-Cancer mRNA Vaccine
(Current as of August 2023)
| Pipelines | Indications | Detailed planning | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| mRNA vaccine | Anticancer | Calculation of candidate substances | |||||
| Delivery Vehicle Development | |||||||
| PK & Efficacy | |||||||
| Preclinical toxicity testing |
Vx Microbiome R&D Pipeline
(as of August 2023)
| Project name | Target | In vitro test | Animal cell experiments | In vivo test | Mass Production | Fungus Production | Human studies |
|---|---|---|---|---|---|---|---|
| Vx_1010 | Regulating the gut microbiome | ||||||
| Vx_1011 | Diabetes/Obesity | ||||||
| Vx_2090 | Boosting immunity | ||||||
| Vx_2091 | Asthma/Atopic Dermatitis | ||||||
| Vx_2092 | Inflammatory bowel disease | ||||||
| Vx_3020 | Liver Health | ||||||
| Vx_7010 | Oral health | ||||||
| Vx_8010 | Women's health | ||||||
| Vx_0010 | Mental health |
Oxford Vacmedix Vaccine
ROP Platform Technology for Personalized Cancer Vaccines/Therapeutics
Our subsidiary company, Oxford Vacmedix, a spin-off from the University of Oxford, is developing personalized vaccines and therapies to combat cancer and infectious diseases using its unique ROP (Recombinant Overlapping Peptide) platform technology. The ROP platform is easier to design and synthesize than traditional vaccines and can be applied to all HLA types, stimulating CD8 and CD4 T cells for greater efficacy. It also enhances immunogenicity and duration of action, with the potential for synergy with other immune oncology agents. Currently, the OVM-200 pipeline is entering phase 1 clinical trials to confirm its potential as an anti-cancer vaccine for serious stage cancers. Recent results have shown stability and responsiveness, and our executives will join the board of Oxford Vacmedix to collaborate on this project and other product development ventures.
(As of August 2023)
| Pipelines | Indications | Detailed planning | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| OVM-200 | Cancer Treatment Vaccines | Manufacture/Pre-clinical | |||||||
| Phase 1a | |||||||||
| Phase 1b |
Avixgen
Avixgen has an excellent pipeline for ophthalmic diseases such as dry eye syndrome and macular degeneration, as well as atopic dermatitis. Avixgen has planned to expedite development of pipeline through expanded collaboration with parent company Dx&Vx to evaluate technology and promote IPO.
(as of August 2023)
| Pipeline | Disease | Research | Pre-Clinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|---|
| AVI-4015 | Dry eye medications | |||||
| AVI-3207 | Macular Degeneration Treatment (Injectable) | |||||
| AVI-3207 | Macular degeneration medications (eye drops) | |||||
| AVI-3307 | Atopic medications | |||||
| ACPD | ACP Platform |